Lung, Phase II
A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
What is the purpose of this trial?
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact firstname.lastname@example.org, or call 877.978.8343 for more information.
- Roy S. Herbst, MD, PhDEnsign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Deputy Director, Yale Cancer Center; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Assistant Dean for Translational Research, Yale School of Medicine; Director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital
- Last Updated12/22/2022
- Study HIC#2000030983